Ensysce Net Receivables vs Total Liab Analysis

ENSC Stock

USD 0.58 0.03 4.90%

Ensysce Biosciences financial indicator trend analysis is much more than just examining Ensysce Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ensysce Biosciences is a good investment. Please check the relationship between Ensysce Biosciences Net Receivables and its Total Liab accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ensysce Biosciences Net Receivables account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Ensysce Biosciences' Net Receivables and Total Liab is 0.67. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Liab in the same time period over historical financial statements of Ensysce Biosciences, assuming nothing else is changed. The correlation between historical values of Ensysce Biosciences' Net Receivables and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Ensysce Biosciences are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Receivables i.e., Ensysce Biosciences' Net Receivables and Total Liab go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Receivables

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Ensysce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ensysce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.At present, Ensysce Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.22, whereas Issuance Of Capital Stock is forecasted to decline to about 8.5 M.

	2023	2024 (projected)
Interest Income	98.6K	93.6K
Tax Provision	281.2K	373.2K

Interest Income Tax Provision

Ensysce Biosciences fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Net Tangible Assets	Warrants	Net Debt	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity
Total Assets		-0.8	0.87	0.96	-0.25	0.87	0.87	0.78	1.0	-0.97	-0.18	0.75	1.0	-0.4	1.0	0.78	-0.79	-0.77	1.0	0.36	-0.56	-1.0	1.0	0.68	-0.73	-0.93
Total Current Liabilities	-0.8		-0.73	-0.73	0.71	-0.78	-0.76	-0.74	-0.82	0.69	0.71	-0.67	-0.82	0.79	-0.83	-0.47	0.68	0.43	-0.82	-0.78	0.8	0.78	-0.82	-0.26	0.92	0.78
Total Stockholder Equity	0.87	-0.73		0.83	-0.24	0.74	0.73	0.86	0.87	-0.84	-0.2	0.88	0.87	-0.36	0.88	0.65	-0.69	-0.66	0.88	0.35	-0.52	-0.87	0.88	0.58	-0.67	-0.8
Retained Earnings	0.96	-0.73	0.83		-0.24	0.82	0.82	0.72	0.96	-0.99	-0.1	0.71	0.96	-0.35	0.96	0.84	-0.6	-0.79	0.96	0.31	-0.34	-0.97	0.95	0.83	-0.77	-0.92
Cash	-0.25	0.71	-0.24	-0.24		-0.2	-0.17	-0.19	-0.28	0.15	0.93	-0.12	-0.28	0.67	-0.29	0.05	0.07	-0.2	-0.28	-0.97	0.56	0.24	-0.3	0.22	0.78	0.2
Other Assets	0.87	-0.78	0.74	0.82	-0.2		1.0	0.91	0.87	-0.83	-0.26	0.87	0.88	-0.66	0.88	0.77	-0.77	-0.68	0.88	0.34	-0.5	-0.86	0.83	0.56	-0.66	-0.98
Cash And Short Term Investments	0.87	-0.76	0.73	0.82	-0.17	1.0		0.91	0.87	-0.83	-0.24	0.86	0.88	-0.64	0.88	0.78	-0.77	-0.68	0.87	0.32	-0.49	-0.86	0.83	0.57	-0.64	-0.98
Common Stock Shares Outstanding	0.78	-0.74	0.86	0.72	-0.19	0.91	0.91		0.78	-0.73	-0.29	0.99	0.79	-0.64	0.79	0.66	-0.73	-0.61	0.79	0.34	-0.5	-0.77	0.75	0.46	-0.61	-0.88
Short Term Investments	1.0	-0.82	0.87	0.96	-0.28	0.87	0.87	0.78		-0.97	-0.21	0.75	1.0	-0.42	1.0	0.77	-0.78	-0.76	1.0	0.39	-0.57	-1.0	1.0	0.67	-0.76	-0.93
Capital Surpluse	-0.97	0.69	-0.84	-0.99	0.15	-0.83	-0.83	-0.73	-0.97		0.02	-0.72	-0.96	0.29	-0.97	-0.87	0.65	0.8	-0.96	-0.24	0.35	0.98	-0.96	-0.83	0.7	0.92
Total Liab	-0.18	0.71	-0.2	-0.1	0.93	-0.26	-0.24	-0.29	-0.21	0.02		-0.21	-0.21	0.82	-0.22	0.16	0.2	-0.22	-0.21	-0.93	0.67	0.15	-0.22	0.39	0.68	0.2
Total Current Assets	0.75	-0.67	0.88	0.71	-0.12	0.87	0.86	0.99	0.75	-0.72	-0.21		0.76	-0.55	0.76	0.68	-0.67	-0.6	0.76	0.27	-0.42	-0.75	0.72	0.49	-0.55	-0.85
Common Stock	1.0	-0.82	0.87	0.96	-0.28	0.88	0.88	0.79	1.0	-0.96	-0.21	0.76		-0.43	1.0	0.77	-0.79	-0.76	1.0	0.39	-0.57	-0.99	1.0	0.67	-0.76	-0.94
Other Current Liab	-0.4	0.79	-0.36	-0.35	0.67	-0.66	-0.64	-0.64	-0.42	0.29	0.82	-0.55	-0.43		-0.44	-0.17	0.42	0.18	-0.43	-0.69	0.58	0.36	-0.39	0.03	0.72	0.57
Net Tangible Assets	1.0	-0.83	0.88	0.96	-0.29	0.88	0.88	0.79	1.0	-0.97	-0.22	0.76	1.0	-0.44		0.77	-0.78	-0.76	1.0	0.39	-0.57	-0.99	1.0	0.67	-0.76	-0.94
Warrants	0.78	-0.47	0.65	0.84	0.05	0.77	0.78	0.66	0.77	-0.87	0.16	0.68	0.77	-0.17	0.77		-0.41	-0.57	0.77	0.09	-0.07	-0.82	0.73	0.8	-0.47	-0.84
Net Debt	-0.79	0.68	-0.69	-0.6	0.07	-0.77	-0.77	-0.73	-0.78	0.65	0.2	-0.67	-0.79	0.42	-0.78	-0.41		0.67	-0.79	-0.21	0.79	0.74	-0.78	-0.28	0.4	0.73
Accounts Payable	-0.77	0.43	-0.66	-0.79	-0.2	-0.68	-0.68	-0.61	-0.76	0.8	-0.22	-0.6	-0.76	0.18	-0.76	-0.57	0.67		-0.76	0.18	0.22	0.76	-0.76	-0.83	0.4	0.74
Non Current Assets Total	1.0	-0.82	0.88	0.96	-0.28	0.88	0.87	0.79	1.0	-0.96	-0.21	0.76	1.0	-0.43	1.0	0.77	-0.79	-0.76		0.39	-0.57	-0.99	1.0	0.67	-0.76	-0.94
Non Currrent Assets Other	0.36	-0.78	0.35	0.31	-0.97	0.34	0.32	0.34	0.39	-0.24	-0.93	0.27	0.39	-0.69	0.39	0.09	-0.21	0.18	0.39		-0.64	-0.35	0.4	-0.22	-0.78	-0.33
Net Receivables	-0.56	0.8	-0.52	-0.34	0.56	-0.5	-0.49	-0.5	-0.57	0.35	0.67	-0.42	-0.57	0.58	-0.57	-0.07	0.79	0.22	-0.57	-0.64		0.5	-0.59	0.17	0.55	0.44
Common Stock Total Equity	-1.0	0.78	-0.87	-0.97	0.24	-0.86	-0.86	-0.77	-1.0	0.98	0.15	-0.75	-0.99	0.36	-0.99	-0.82	0.74	0.76	-0.99	-0.35	0.5		-0.99	-0.72	0.73	0.93
Retained Earnings Total Equity	1.0	-0.82	0.88	0.95	-0.3	0.83	0.83	0.75	1.0	-0.96	-0.22	0.72	1.0	-0.39	1.0	0.73	-0.78	-0.76	1.0	0.4	-0.59	-0.99		0.66	-0.76	-0.9
Non Current Liabilities Total	0.68	-0.26	0.58	0.83	0.22	0.56	0.57	0.46	0.67	-0.83	0.39	0.49	0.67	0.03	0.67	0.8	-0.28	-0.83	0.67	-0.22	0.17	-0.72	0.66		-0.4	-0.69
Other Current Assets	-0.73	0.92	-0.67	-0.77	0.78	-0.66	-0.64	-0.61	-0.76	0.7	0.68	-0.55	-0.76	0.72	-0.76	-0.47	0.4	0.4	-0.76	-0.78	0.55	0.73	-0.76	-0.4		0.72
Other Stockholder Equity	-0.93	0.78	-0.8	-0.92	0.2	-0.98	-0.98	-0.88	-0.93	0.92	0.2	-0.85	-0.94	0.57	-0.94	-0.84	0.73	0.74	-0.94	-0.33	0.44	0.93	-0.9	-0.69	0.72

Click cells to compare fundamentals

Ensysce Biosciences Account Relationship Matchups

Ensysce Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	196.5M	351.8K	16.4M	5.9M	2.7M	2.6M
Total Current Liabilities	2.8M	7.0M	16.5M	9.5M	3.3M	6.2M
Total Stockholder Equity	186.2M	(6.4M)	(8.2M)	(4.0M)	(651.3K)	(618.7K)
Retained Earnings	2.5M	(56.0M)	(85.8M)	(110.9M)	(121.6M)	(115.5M)
Cash	1.1M	194.2K	12.3M	3.1M	1.1M	1.1M
Other Assets	5K	3.8K	754.8K	585.9K	527.3K	500.9K
Cash And Short Term Investments	1.1M	194.2K	12.3M	3.1M	1.1M	1.1M
Common Stock Shares Outstanding	98.3K	68.8K	84.0K	179.9K	2.3M	3.9M
Long Term Debt Total	566.3K	791.3K	4.4M	140.2K	161.2K	153.1K
Liabilities And Stockholders Equity	196.5M	351.8K	16.4M	5.9M	2.7M	2.6M
Capital Surpluse	2.9M	2.5M	78.0M	107.2M	123.3M	129.5M
Total Liab	10.3M	7.0M	24.6M	9.9M	3.4M	3.2M
Total Current Assets	1.2M	347.9K	15.7M	5.3M	2.3M	2.2M
Short Term Debt	2.6M	4.3M	12.7M	4.3M	854.7K	812.0K
Common Stock	181.2M	1.6K	2.5K	642.0	315.0	299.25
Other Current Liab	2.8M	856.0K	3.4M	2.3M	542.3K	515.1K
Net Debt	(494.9K)	4.1M	483.4K	1.3M	(268.9K)	(255.5K)
Accounts Payable	540.8K	1.7M	301.1K	2.9M	1.9M	1.4M
Non Current Assets Total	195.3M	3.9K	754.8K	585.9K	419.2K	398.3K
Non Currrent Assets Other	(351.0)	3.8K	(24.7B)	558.7K	419.2K	440.2K
Non Current Liabilities Total	7.6M	6.8M	8.1M	450.5K	26.4K	25.1K
Other Current Assets	138.6K	153.7K	3.4M	2.2M	1.2M	1.3M
Other Stockholder Equity	2.5M	49.5M	77.7M	106.9M	120.9M	127.0M

Pair Trading with Ensysce Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ensysce Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ensysce Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Ensysce Stock

0.62

EVOK

Evoke Pharma

Pair Corr

Moving against Ensysce Stock

0.74	LLY	Eli Lilly Earnings Call This Week	Pair Corr
0.73	VKTX	Viking Therapeutics	Pair Corr
0.73	OGN	Organon	Pair Corr
0.68	HCWB	HCW Biologics	Pair Corr
0.68	KRYS	Krystal Biotech Financial Report 13th of May 2024	Pair Corr

The ability to find closely correlated positions to Ensysce Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ensysce Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ensysce Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ensysce Biosciences to buy it.

The correlation of Ensysce Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ensysce Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ensysce Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Ensysce Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:

How To Invest In Ensysce

Details

Is Ensysce Stock a good investment?

Details

What is Ensysce Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Ensysce Stock analysis

When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.

	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world

Is Ensysce Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.69)

Revenue Per Share

0.985

Quarterly Revenue Growth

(0.64)

Return On Assets

(1.56)

Return On Equity

(13.20)

The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ensysce Net Receivables vs Total Liab Analysis

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Total Liab

Ensysce Biosciences fundamental ratios Correlations

Ensysce Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ensysce Biosciences fundamental ratios Accounts

Pair Trading with Ensysce Biosciences

Moving together with Ensysce Stock

Moving against Ensysce Stock

Complementary Tools for Ensysce Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Investments	+ 1.0	Total Assets
Common Stock	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Retained Earnings Total Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Other Assets

Common Stock Total Equity	- 1.0	Short Term Investments
Common Stock Total Equity	- 1.0	Total Assets
Retained Earnings Total Equity	- 0.99	Common Stock Total Equity
Common Stock Total Equity	- 0.99	Non Current Assets Total
Common Stock Total Equity	- 0.99	Net Tangible Assets
Common Stock Total Equity	- 0.99	Common Stock